Serum Institute to price Covid vaccine at less than Rs 250/dose

18

By Ashish Srivastava
New Delhi, Aug 7 |
The Serum Institute of India would introduce candidate vaccines from AstraZeneca and Novavax for COVID-19 at less than Rs 250 per dose in India. The Pune-based institute would offer up to 100 million doses at a price capped at $3 for 92 low and middle-income countries (LMIC), including India, SII announced on Friday.

As per SII, the vaccines will be available as early as the first half of 2021 after gaining approvals and qualifications from the World Health Organization (WHO). The SII also said that if successful, Novavax’s candidate will be available to all 92 countries while AstraZeneca’s candidate vaccine will be available to 57 Gavi-eligible countries.

The development comes after the SII entered into a collaboration with Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation as part of COVAX agreement. Under the agreement, the SII will receive an upfront capital of $150 million from the Bill & Melinda Gates Foundation via Gavi to enhance the capacity to manufacture and distribute the potential vaccine to candidates on a large scale after gaining regulatory approval and WHO prequalification. The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax.

Dr Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), commented, “India has demonstrated consistent capability in delivering low-cost and high-quality medical research, while also maintaining technical and scientific rigour. ICMR is deeply supportive of our cutting edge vaccine research and manufacturing prowess, of which SII is one prominent example. This partnership signifies yet another step in India’s efforts to bolster the fight against this global pandemic.”

SII has signed two agreements for the supply of Covid-19 vaccines, the first being AstraZeneca-Oxford’s candidate, for which the company has agreed to produce up to 1 billion doses for low and middle-income countries. The Oxford University vaccine candidate has received permission to start phase-2 and 3 trials in India last week.

The second agreement is with the US-based Novavax that has granted the company exclusive and non-exclusive licences for development, co-formulation, filling and finishing, registration and commercialisation of its NVX-CoV2373 vaccine product for the SARS-CoV-2 virus. Novavax trials are yet to start in India.

The deal, built on a memorandum of understanding (MoU) between AstraZeneca and Gavi, reportedly guarantees 300 million doses of AstraZeneca’s candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification, the statement by the SII read.

“The rampant spread of the virus has rendered the entire world in an unimaginable halt of uncertainty. And to ensure maximum immunisation coverage and contain the pandemic, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures. Through this association, we seek to ramp up our constant efforts to save the lives of millions of people from this dreadful disease,” said Adar Poonawalla, CEO of Serum Institute of India.

Source: IANS

Sponsors Posts

Policybazaar Unveils its new brand campaign "AapKiSideHai"

Policybazaar Unveils its new brand campaign

Akshay Kumar delivers the brand’s promise of always being on the customer’s side

Gurugram, 19th Sept, 2020: Policybazaar.com (Twitter handle: PolicyBazaar), India’s largest online insurance marketplace with over 10 million customers, showcases its commitment to customers in its new television campaign “AapKiSideHai”. The new ad campaign featuring Policybazaar brand ambassador, Akshay Kumar, highlights the brand’s promise of embracing a holistic customer centric approach while helping to bridge the insurance protection gap in India.

Policybazaar’sAapKiSideHai campaign seeks to reassure its customers on being a dependable Insurance partner for them, every step of the way. The brand has always focused on distributing products like term insurance, health insurance, zero commission ULIP’s and motor insurance that are optimal from a customer perspective. Policybazaar is now extending the brand promise beyond the purchase experience to ensure that consumers get the highest levels of service throughout the policy lifecycle.

The new brand campaign reinforces Policybazaar core value of putting the customer first by delivering on its promise of providing a trusted platform for all types of insurance products. The brand is committed to guiding the customer throughout the insurance journey, starting from recommending the right products at affordable pricing, ensuring thatthe policy issuance process is smooth and fast, and, to providing services and claims assistance when needed.

“While we continue to highlight the importance of Health & Term life Insurance through our marketing campaigns, with the brand promise of Policybazaar AapKiSideHai, we also intend to position Policybazaar as a customer centric brand, that is committed to stand by its customers, both pre and post purchase”, said Samir Sethi, Head of Brand Marketing, Policybazaar.com. The new ad series highlights Policybazaar’s unparalleled support to customers, while providing them with the ease of comparing and buying term and health plans online with guidance at each & every step.

Speaking about the TVC launch, Sharat Dhall, Chief Operating Officer, Policybazaar.com said, “Our ultimate aim is to provide 360-degree assistance to customers that starts from when the policy is bought, to provide assistance when the claim is paid out, should such a situation arise. Winning and maintaining customer trust is a strong ethos within the company and this campaign reflects that. At a time when the world is grappling with a crisis like no other, the brand intends to instill confidence in the customers’ buying decisions by assuring them protection of their futures with the right insurance products & thorough assistance throughout the journey.”

The new brand campaign in its series displays moments of indecision that people may have while investing in protection products. It addresses these queries &emphasizes the importance of nurturing a bond with the consumers thereby creating customer delight.

LEAVE A REPLY

Please enter your comment!
Please enter your name here